WARSAW, Nov 7 (Reuters) - The Head of Poland's insulin maker Bioton, Janusz Guy, has stepped down and will be replaced by Slawomir Ziegert, the company said in a statement late on Friday.
Bioton's main shareholder, Ryszard Krazue, said the resignation was due to private reasons and that the company was considering selling its antibiotics arm.
'The future lies in developing biotechnology,' Krauze was quoted on Saturday by daily Parkiet as saying. 'The cash obtained this way we could invest in selling highly profitable insulin or other biotech products.'
Krauze added he had great hopes in regard to Ziegert and wanted the company's restructuring programme to be finalised by the end of the year.
Bioton is to publish its third-quarter results on Nov.16.
(Writing by Gabriela Baczynska) Keywords: POLAND BIOTON/ (gabriela.baczynska@reuters.com; Reuters Messaging: gabriela.baczynska.reuters.com@reuters.net; tel. + 48 22 653 97 22; editing by Chris Pizzey) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
Bioton's main shareholder, Ryszard Krazue, said the resignation was due to private reasons and that the company was considering selling its antibiotics arm.
'The future lies in developing biotechnology,' Krauze was quoted on Saturday by daily Parkiet as saying. 'The cash obtained this way we could invest in selling highly profitable insulin or other biotech products.'
Krauze added he had great hopes in regard to Ziegert and wanted the company's restructuring programme to be finalised by the end of the year.
Bioton is to publish its third-quarter results on Nov.16.
(Writing by Gabriela Baczynska) Keywords: POLAND BIOTON/ (gabriela.baczynska@reuters.com; Reuters Messaging: gabriela.baczynska.reuters.com@reuters.net; tel. + 48 22 653 97 22; editing by Chris Pizzey) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
